We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

NVDA:NASDAQNVIDIA Corporation Analysis

Data as of 2026-08-23 - not real-time

$214.72

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

NVIDIA Corporation is priced at $214.72 and its moving averages line up in bullish order, the shorter sitting above the longer. Across the trailing 30 sessions it gained 1.8%. Momentum indicators put RSI at 51.0 (neutral) with MACD reading bearish. The recent range runs from support at $190.01 up to resistance at $227.92.
Multiples put this in fair territory: 32.9 times earnings against the sector's 35.2. Consensus targets land 41.9% above where the shares trade now. Revenue is growing at 85.2% on a 63.0% profit margin. The 0.47% dividend yield looks covered by current payout levels.
Risk comes out at 7 of a possible 10, a elevated reading. With 30-day volatility of 37.6%, a beta of 1.88 and a maximum drawdown of 20.2%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 6 out of 10.

Top Market Events

Space Exploration Technologies Corp. NASDAQ:SPCX beat Wall StreetNvidia NASDAQ: NVDA shareholders holding 100 shares of the firm are expected to receive $25 when the company’s next...The problem with AI valuations is that infrastructure spending is running far ahead of the revenue available to support...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 195.29
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 32.9 versus sector average of 35.2
  • Trading above the 200-day average of 195.29

Long Term

> 3 years
Positive
Model confidence: 6/10

Key Factors

  • P/E of 32.9 versus sector average of 35.2
  • Analyst targets imply +41.9% versus the current price
  • Profit margin of 63.0% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth85.20%
Profit Margin62.97%
P/E Ratio32.9
ROE114.29%
ROA52.73%
Debt/Equity6.55
P/B Ratio26.6
Op. Cash Flow$125.6B
Free Cash Flow$46.3B
Industry P/E35.2

Technical Analysis

TrendBullish
RSI51.0
Support$190.01
Resistance$227.92
MA 20$213.18
MA 50$207.58
MA 200$195.29
MACDBearish
VolumeDecreasing
Fear & Greed Index94.41

Valuation

Fair Value$68.48
Target Price$304.73
Upside/Downside41.92%
GradeFair
TypeGrowth
Dividend Yield0.47%

Risk Assessment

Beta1.88
Volatility37.65%
Sector RiskHigh
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.